|
XVivo Perfusion AB (0RKL.L) Avaliação DCF |
- ✓ Totalmente Editável: Adapte-Se Às Suas Necessidades No Excel Ou Planilhas
- ✓ Design Profissional: Modelos Confiáveis E Padrão Da Indústria
- ✓ Pré-Construídos Para Uso Rápido E Eficiente
- ✓ Não É Necessária Experiência; Fácil De Seguir
Xvivo Perfusion AB (publ) (0RKL.L) Bundle
Procurando avaliar o valor intrínseco do XVivo Perfusion AB (publ)? Nossa calculadora DCF (0RKLL) integra dados do mundo real com recursos abrangentes de personalização, permitindo refinar suas previsões e aprimorar suas estratégias de investimento.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 179.9 | 258.4 | 415.3 | 597.5 | 822.4 | 1,204.6 | 1,764.5 | 2,584.6 | 3,785.7 | 5,545.2 |
| Revenue Growth, % | 0 | 43.66 | 60.73 | 43.88 | 37.63 | 46.48 | 46.48 | 46.48 | 46.48 | 46.48 |
| EBITDA | -43.3 | 39.2 | 39.2 | 126.6 | 88.4 | 78.2 | 114.5 | 167.7 | 245.7 | 359.8 |
| EBITDA, % | -24.09 | 15.17 | 9.44 | 21.18 | 10.74 | 6.49 | 6.49 | 6.49 | 6.49 | 6.49 |
| Depreciation | 13.4 | 32.3 | 15.8 | 30.9 | .0 | 69.6 | 101.9 | 149.3 | 218.7 | 320.4 |
| Depreciation, % | 7.43 | 12.48 | 3.81 | 5.16 | 0 | 5.78 | 5.78 | 5.78 | 5.78 | 5.78 |
| EBIT | -56.7 | 6.9 | 23.4 | 95.7 | 88.4 | 8.6 | 12.6 | 18.4 | 26.9 | 39.5 |
| EBIT, % | -31.52 | 2.69 | 5.64 | 16.02 | 10.74 | 0.7117 | 0.7117 | 0.7117 | 0.7117 | 0.7117 |
| Total Cash | 353.4 | 398.7 | 246.5 | 546.1 | 415.5 | 966.8 | 1,416.1 | 2,074.3 | 3,038.3 | 4,450.3 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 40.2 | 52.0 | 94.5 | 98.1 | .0 | 196.7 | 288.2 | 422.1 | 618.3 | 905.6 |
| Account Receivables, % | 22.34 | 20.14 | 22.76 | 16.42 | 0 | 16.33 | 16.33 | 16.33 | 16.33 | 16.33 |
| Inventories | 59.4 | 77.6 | 106.6 | 141.6 | 227.4 | 337.4 | 494.2 | 723.9 | 1,060.3 | 1,553.1 |
| Inventories, % | 33 | 30.03 | 25.66 | 23.7 | 27.65 | 28.01 | 28.01 | 28.01 | 28.01 | 28.01 |
| Accounts Payable | 14.5 | 21.4 | 38.5 | 36.1 | .0 | 76.2 | 111.7 | 163.6 | 239.6 | 350.9 |
| Accounts Payable, % | 8.04 | 8.3 | 9.26 | 6.03 | 0 | 6.33 | 6.33 | 6.33 | 6.33 | 6.33 |
| Capital Expenditure | -64.7 | -94.1 | -130.9 | -43.0 | .0 | -267.7 | -392.1 | -574.3 | -841.2 | -1,232.1 |
| Capital Expenditure, % | -35.96 | -36.41 | -31.53 | -7.2 | 0 | -22.22 | -22.22 | -22.22 | -22.22 | -22.22 |
| Tax Rate, % | 13.89 | 13.89 | 13.89 | 13.89 | 13.89 | 13.89 | 13.89 | 13.89 | 13.89 | 13.89 |
| EBITAT | -43.3 | 8.5 | 19.3 | 93.0 | 76.1 | 7.6 | 11.1 | 16.3 | 23.8 | 34.9 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -179.7 | -76.4 | -150.2 | 39.7 | 52.4 | -421.0 | -491.8 | -720.4 | -1,055.2 | -1,545.6 |
| WACC, % | 14.01 | 14.01 | 14.01 | 14.01 | 14.01 | 14.01 | 14.01 | 14.01 | 14.01 | 14.01 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -2,660.9 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -1,577 | |||||||||
| Terminal Value | -13,130 | |||||||||
| Present Terminal Value | -6,817 | |||||||||
| Enterprise Value | -9,478 | |||||||||
| Net Debt | -416 | |||||||||
| Equity Value | -9,063 | |||||||||
| Diluted Shares Outstanding, MM | 32 | |||||||||
| Equity Value Per Share | -286.18 |
Benefits of Choosing Us
- Customizable Excel Template: A fully editable Excel-based DCF Calculator featuring pre-populated financial data for Xvivo Perfusion AB (publ) (0RKLL).
- Accurate Data: Access to historical data and projected estimates (highlighted in the yellow cells).
- Flexible Forecasting: Adjust key assumptions such as revenue growth, EBITDA percentage, and WACC.
- Instant Calculations: Quickly observe how your inputs influence the valuation of Xvivo Perfusion AB (publ) (0RKLL).
- Professional Instrument: Designed for investors, CFOs, consultants, and financial analysts.
- Intuitive User Interface: Organized for simplicity and accessibility, complete with step-by-step guidance.
Core Advantages
- Accurate Financial Data: Gain access to reliable historical figures and future forecasts specific to Xvivo Perfusion AB (publ) (0RKLL).
- Flexible Assumptions for Forecasting: Modify highlighted cells for key metrics such as WACC, growth rates, and profit margins.
- Automated Calculations: Instant updates for DCF, Net Present Value (NPV), and cash flow assessments.
- Interactive Visual Dashboard: Clear charts and summaries to help you understand your valuation insights visually.
- Designed for All Users: An intuitive layout tailored for investors, CFOs, and consultants, whether novice or expert.
How It Operates
- Download the Template: Gain immediate access to the Excel-based Xvivo Perfusion AB (0RKLL) DCF Calculator.
- Input Your Assumptions: Modify the yellow-highlighted cells for growth rates, WACC, profit margins, and other factors.
- Instant Calculations: The model will automatically recalculate the intrinsic value of Xvivo Perfusion AB (0RKLL).
- Test Scenarios: Experiment with different assumptions to analyze potential changes in valuation.
- Analyze and Decide: Utilize the outcomes to inform your investment or financial strategies.
Why Opt for This Calculator?
- Precision: Utilizes accurate Xvivo Perfusion AB (publ) (0RKLL) financials for reliable data.
- Versatility: Tailored for users to easily test and adjust inputs as needed.
- Efficiency: Eliminate the complexities of creating a DCF model from the ground up.
- Expert-Level: Crafted with the precision and usability expected at the CFO level.
- Accessible: Intuitive interface makes it easy for those without extensive financial modeling skills.
Who Can Benefit from This Product?
- Institutional Investors: Develop comprehensive and accurate valuation models for investment analysis.
- Corporate Finance Departments: Evaluate valuation scenarios to inform strategic decisions.
- Financial Consultants: Offer clients precise valuation perspectives for Xvivo Perfusion AB (0RKLL) stock.
- Academic Students and Instructors: Utilize real-world data to enhance financial modeling skills and education.
- Healthcare Technology Enthusiasts: Gain insights into how medical tech firms like Xvivo Perfusion AB (0RKLL) are valued in the marketplace.
Contents of the Template
- Pre-Filled DCF Model: Xvivo Perfusion AB’s financial data preloaded for immediate utilization.
- WACC Calculator: Comprehensive calculations for Weighted Average Cost of Capital.
- Financial Ratios: Assess Xvivo Perfusion AB's profitability, leverage, and efficiency metrics.
- Editable Inputs: Modify assumptions such as growth rates, margins, and CAPEX to suit your scenarios.
- Financial Statements: Access annual and quarterly reports for thorough analysis.
- Interactive Dashboard: Effortlessly visualize essential valuation metrics and outcomes.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.